Key Market Drivers, Trends, and Forecast for the Global Tardive Dyskinesia Therapeutics Industry
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Will the Tardive Dyskinesia Therapeutics Market Evolve in Terms of Growth and Size by 2029?
In recent years, there has been a substantial growth in the size of the tardive dyskinesia therapeutics market. From a market worth $2.9 billion in 2024, it is projected to increase to $3.12 billion in 2025 with a compound annual growth rate (CAGR) of 7.5%. This upward trajectory can be linked to several factors including an increased incidence of tardive dyskinesia, a heightened global count of patients suffering from schizophrenia and bipolar disorder, elevated awareness and diagnosis rates, a growing consumption of both atypical and typical antipsychotic drugs, and an ageing population.
In the coming years, we can expect an impressive expansion in the market for tardive dyskinesia therapeutics. The market valuation is predicted to reach $4.11 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.2%. This anticipated surge over the forecast period can be ascribed to factors such as an escalating mental health disease load, broadening R&D endeavors, amplified investments by pharma organizations, increasing inclination towards personalized healthcare, and an enhanced health care infrastructure. Looking ahead, major projected trends include alliances between pharmaceutical firms and research institutions for innovative treatments, the creation of extended-release formulas, the introduction of generics, and regulatory benefits like orphan drug designation, as well as technological progress in medicine delivery systems.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24718&type=smp
What factors are expected to fuel Tardive Dyskinesia Therapeutics market growth in the coming years?
Growing instances of mental health disorders are anticipated to fuel the expansion of the tardive dyskinesia therapeutics market in the future. These disorders, characterized by the impact on a person’s thoughts, emotions, behavior, and overall functioning, often lead to substantial distress or complications in everyday life. The move towards digital communications and fast-paced living, resulting in decreased intimate face-to-face interactions, has contributed to rising mental health disorders. This lifestyle shift has increased feelings of loneliness and emotional strain due to heightened social isolation. Tardive dyskinesia therapeutics assist patients with mental disorders by controlling involuntary movements induced by prolonged use of antipsychotic medication, thereby enhancing treatment compliance and overall life quality. For example, the National Alliance On Mental Illness, a US organization, predicted that among individuals aged 18-44 in the U.S., nearly 600,000 hospitalizations per year result from psychosis spectrum and mood disorders by 2024. Hence, the growing prevalence of mental health disorders is acting as a catalyst for the growth of the tardive dyskinesia therapeutics market.
What Are The Key Findings From The Segmentation Analysis Of The Tardive Dyskinesia Therapeutics Market?
The tardive dyskinesia therapeutics market covered in this report is segmented –
1) By Drug: Deutetrabenazine, Valbenazine, Other Drugs
2) By Product Type: Solid Dosage Forms, Tablets, Capsules, Liquid Dosage Form, Injection
3) By Application: Antipsychotic-Induced Tardive Dyskinesia, Other Drug-Induced Tardive Dyskinesia, Idiopathic Tardive Dyskinesia
4) By End-User: Hospitals, Clinics, Specialty Treatment Centers, Homecare Settings
Sub Segments:
1) By Deutetrabenazine: Dosage Forms, Line Of Therapy, Distribution Channel
2) By Valbenazine: Dosage Forms, Patient Age Group, Distribution Channel
3) By Other Drugs: Drug Class Or Type, Dosage Forms, Treatment Duration
Which Trends Are Expected To Shape The Future Of The Tardive Dyskinesia Therapeutics Market?
Leading enterprises in the tardive dyskinesia therapeutics market are prioritising the development of enhanced products such as once-daily treatment alternatives. These are medications or therapies structured to be taken once in a day, streamlining dosage routines and boosting patient consistency. For example, Teva Pharmaceutical Industries Limited, a bio-pharmaceutical firm based in Israel, disclosed the sanction of their AUSTEDO XR tablets for treating adults with tardive dyskinesia and Huntington’s disease chorea by the U.S. Food and Drug Administration (FDA) in May 2024. The recent sanctioning of AUSTEDO XR avails patients with verified efficacy in managing involuntary actions combined with the advantage of a single-pill dosage taken once a day. This new form gives therapeutically clinical doses corroborated by essential clinical tests. It’s also accessible in four varied tablet strengths: 30 mg, 36 mg, 42 mg, and 48 mg.
What Are The Most Active Companies In The Tardive Dyskinesia Therapeutics Market Today?
Major companies operating in the tardive dyskinesia therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lundbeck A/S, Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Neurocrine Biosciences Inc., Luye Pharma Ltd., Lannett Co. Inc., SteriMax Inc., Zydus Cadila Healthcare Ltd., Adamas Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, SOM Biotech Ltd., Addex Therapeutics
Get The Full Report Here:
Which Regional Markets Are Attracting The Most Investment In Tardive Dyskinesia Therapeutics?
North America was the largest region in the tardive dyskinesia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tardive dyskinesia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24718&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
